Data & Technology

As safety data grows in scale and complexity, AI-powered pharmacovigilance is emerging as a strategic imperative—helping drugmakers improve detection, reduce risk, and strengthen commercial performance.

AI-powered control towers and digital twins are emerging as essential tools to prevent costly supply chain failures and restore operational reliability.

In today’s Pharma Pulse, new trials confirm AI chatbots are a successful and sustainable tool for increasing pneumococcal vaccine uptake among older adults and much more.

Artificial intelligence is fundamentally transforming medical affairs from a reactive function into a strategic partner.

When intelligence flows across clinical, access, and engagement channels, commercialization shifts from reactive to predictive, giving teams the real-time edge to win in a fast-moving market.

In the fourth part of her Pharma Commerce video interview, Christy Christian, senior industry principal with Kinaxis, shares how reducing inefficiencies cuts waste, preserves profitability, and ultimately lowers consumer prices while increasing production capacity to meet rising demand.

A review of COVID-19 vaccine access inequities, emerging cardioprotective data for semaglutide, and Experity’s integration with Amazon Pharmacy highlights the shifting dynamics of patient access, clinical innovation, and digital-first care delivery in today’s Pharma Pulse.

In fourth part of his Pharma Commerce video interview, Faisal Khan, a GRC solutions expert with Vanta, explains how tools like Vanta offer real-time visibility, safeguard patient data, and help prevent costly violations before they occur.

A new partnership integrates Amazon Pharmacy into Experity’s urgent care platform, enabling in-clinic prescription ordering, faster fulfillment, and improved treatment adherence through streamlined digital workflows.

The nationally licensed pharmacy network now supports Ethereum, Solana, and XRP across all retail locations, marking a major step toward faster, more transparent payments—and laying the groundwork for a blockchain-based prescription drug payment system.

In third part of his Pharma Commerce video interview, Faisal Khan, a GRC solutions expert with Vanta, emphasizes the need for a risk-based approach—grounded in clear policies, defined criteria, and tailored mitigation plans—to ensure third-party partnerships remain compliant and secure.

How next-generation AI-driven traceability hubs can transform pharmaceutical serialization from a compliance requirement into a business advantage, while enabling real-time supply chain visibility, faster issue resolution, and greater operational efficiency across the global drug distribution network.

In second part of his Pharma Commerce video interview, Faisal Khan, a GRC solutions expert with Vanta, urges organizations to move beyond one-time vetting toward continuous monitoring, contractual accountability, and shared responsibility for HIPAA compliance.

In first part of his Pharma Commerce video interview, Faisal Khan, a GRC solutions expert with Vanta, explains how excessive data access and poor visibility into data flows remain leading causes of HIPAA-related incidents.

Lance Hill, CEO of Within3, discusses how AI-driven decision support tools are helping pharmaceutical companies achieve launch excellence while maintaining regulatory compliance and data integrity.

In the final part of her Pharma Commerce video interview, Jen Butler, CCO at Pleio, emphasizes that as digital tools become central to patient support, there is value to balancing technology with empathy.

At LogiPharma USA, industry leaders from Tive, McKesson, and the broader healthcare logistics community discussed the sector’s transition from passive monitoring to real-time control, the growing influence of advanced therapies, and the importance of diversity and innovation in shaping the future of pharma supply chains.

This episode of Pharma Pulse covers Alkermes’ acquisition of Avadel Pharmaceuticals to expand its portfolio, BioNTech’s public exchange offer for CureVac to strengthen its mRNA pipeline, and a new report revealing how US medical device manufacturers are adopting digital-first models to boost compliance and patient engagement.

Kala Shankle, JD, HDA’s vice president of regulatory affairs, describes how at this year’s seminar, attendees emphasized pragmatic approaches to achieving full compliance while anticipating upcoming FDA rules that could reshape wholesale and 3PL licensure standards across the pharma supply chain.

In the third part of her Pharma Commerce video interview, Linda Malek, JD, partner at Crowell & Moring, explains how healthcare organizations can harmonize both approaches by prioritizing fairness, transparency, and adaptable systems.

In a video interview with Pharma Commerce, Mark Lee, Marqvision’s founder and CEO, and Sean O’Hearen, founder and principal consultant at 1st Line Partners, warn that counterfeiters are rapidly leveraging AI to create fake websites, social profiles, and manipulated product content—outpacing traditional protections and highlighting widespread underreporting of falsified medicines.

Krenar Komoni, founder and CEO of Tive, predicts that AI-driven automation and its accelerating impact on pharmaceutical supply chains will remain a headline topic at LogiPharma USA, as the industry faces growing pressure to innovate while balancing strict regulatory requirements.

In the final part of his Pharma Commerce video interview, Shawn Opatka, VP and GM, Honeywell Life Sciences, explains that as pharma quality systems evolve, AI is shifting from reactive problem-solving to proactive, closed-loop risk prevention, enhancing operator insight, decision-making, and continuous process improvement.

Ammie McAsey, SVP of Supply Chain Operations, McKesson, explains the critical role of real-time visibility, digital tools, and cold chain innovation in ensuring product quality, reducing disruptions, and strengthening patient care.

In the second part of his Pharma Commerce video interview, Shawn Opatka, VP and GM, Honeywell Life Sciences, notes that nearly all pharma organizations are experimenting with AI to address labor shortages, data challenges, and regulatory demands, but full-scale adoption remains on the horizon as companies balance innovation with compliance.